Director/PDMR Shareholding

RNS Number : 6122L

MGC Pharmaceuticals Limited

13 September 2021

 

MGC Pharmaceuticals Ltd.

PDMR Notifications

13 September 2021

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company'),   a European based bio-pharma company specialising in the production and development of phytomedicines, wishes to advise that the following Persons Discharging Managerial Responsibilities ( PDMR ) have been issued shares in MGC Pharma as a result of exercising Performance Rights granted under an Employee Incentive Plan, details of which were announced to the market on 14 May 2021.

A copy of the Announcement made on the 14th of May can be found at the following URL:

https://wcsecure.weblink.com.au/pdf/MXC/02374892.pdf  

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Daniel Kendall
2	Reason for the notification
(a)	Position		Chief Financial Officer
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		MGC Pharmaceuticals Limited
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Fully Paid Ordinary Shares
(b)	Identification Code (ISIN)		AU000000MXC6
(c)	Nature of transaction		Issued of shares on exercise of Performance Rights issued under an Employee Share Plan
(d)	Currency	Price		Volume	Total
	AUD	$0.06		300,000	$18,000
	Aggregated information
	AUD	$0.06		300,000	$18,000
(e)	Date of transaction		2021-09-09
(f)	Place of transaction		Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Rachel Kerr
2	Reason for the notification
(a)	Position		Company Secretary
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		MGC Pharmaceuticals Limited
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Fully Paid Ordinary Shares
(b)	Identification Code (ISIN)		AU000000MXC6
(c)	Nature of transaction		Issued of shares on exercise of Performance Rights issued under an Employee Share Plan
(d)	Currency	Price		Volume	Total
	AUD	$0.06		600,000	$36,000
	Aggregated information
	AUD	$0.06		600,000	$36,000
(e)	Date of transaction		2021-09-09
(f)	Place of transaction		Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Ron Lipsky
2	Reason for the notification
(a)	Position		VP of Business Development and International Relations
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		MGC Pharmaceuticals Limited
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Fully Paid Ordinary Shares
(b)	Identification Code (ISIN)		AU000000MXC6
(c)	Nature of transaction		Issued of shares on on exercise of Performance Rights issued under an Employee Share Plan
(d)	Currency	Price		Volume	Total
	AUD	$0.06		600,000	$36,000
	Aggregated information
	AUD	$0.06		600,000	$36,000
(e)	Date of transaction		2021-09-09
(f)	Place of transaction		Outside a trading venue

--Ends--

Authorised for release by the Executive Chair, for further information please contact:

MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director [phone] [e-mail]	MGC Pharmaceuticals Ltd David Lim Company Secretary [phone] [e-mail]
UK Broker - Turner Pope Andy Thacker [phone] [e-mail]	UK PR Advisors - Tavistock Charles Vivian / Tim Pearson [phone] [e-mail]

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally.  The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline. 

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.  

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

END

 

 

DSHBSGDCDSBDGBX